We LOVE this company and its potential. LONG @$3.00 per share, target price $12.00 per share r with love, Hampton
hmmmm. Interesting. Well, if you are Surf, I assume this is not a pump and dump. That being said....It is a penny stock dude. Total market cap of 276M. Generation of human tissue via 3D printing. It sounds good... but I wouldn't mortgage granny's place just yet. Only $12,800 sales per employee. Its not exactly BMY @ 620K/employee. I'd get out today with a 4% gain.
I am very serious about this stock. It will be a 400% plus winner. Mark my words, friends. Peace Hampton
Its on my watchlist. Go ONVO. You could be in the running for an award on the cruise if you're correct.
Hi there, Over what kind of time are you expecting this price increase and if I may ask what do you see in this company to makie you expect a price this high? Thanks.
Continuation off your other thread... So they have patent rights, through their founder at the Univ of Missouri. Here's a press release from today, which explains today's pop.. SAN DIEGO, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, is presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models. This data is being presented at the TERMIS-Americas Meeting in San Diego. “With a critical shortage of donor organs and few alternatives to transplantation, Organovo is using its 3D bioprinting technology to develop novel therapeutic tissues for direct surgical implantation,” said Eric Michael David, M.D., J.D., chief strategy officer and executive vice president of preclinical development, Organovo. “Our preclinical data show rapid vascularization and tissue engraftment, and evidence of function and durability of our 3D bioprinted human liver tissue over several weeks. Most importantly, we see evidence of stable production of key human liver proteins in the animal bloodstream, and tissue staining for key human metabolic enzymes. The presence of these enzymes provides an important first step in demonstrating the capability of this tissue to treat inborn errors of metabolism, a key indication we are targeting.” Organovo implanted its 3D bioprinted human liver tissue patches onto the livers of NOD/SCID mice. The tissue was composed of human hepatocytes and select non-parenchymal cells. Function of the 3D bioprinted human liver tissue patches was seen via detection of human albumin, alpha-1-anti-trypsin and fibrinogen in the circulating blood of the mice as early as seven days and for at least 28 days post-implantation. Histopathologic evaluation of the implanted therapeutic tissue revealed retention of the bioprinted cellular organization through 28 days post-implantation, with robust staining for key human metabolic enzymes associated with inborn errors of metabolism, such as Fumarylacetoacetate Hydrolase (FAH) deficiency and Ornithine Transcarbamylase (OTC) deficiency. The tissues remained intact on the animal liver and were well tolerated by the animals. Taken together, these data support further preclinical development of Organovo’s 3D bioprinted liver tissue for therapeutic use. Focusing first on acute-on-chronic liver failure and pediatric inborn errors of metabolism, both indications where a bioprinted liver patch may show therapeutic benefits, Organovo intends to submit an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its therapeutic liver tissue in three to five years. The total addressable market opportunity for these initial indication areas exceeds $3 billion in the U.S. As appropriate, Organovo will pursue breakthrough therapy designation, clinical development outside the United States, and other opportunities to help accelerate time to market. About Organovo Holdings, Inc. Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets. Organovo is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
Now this is interesting... they are hiring a patent attorney. Unless its a fake lol. (I don't trust anything ) http://www.attorneyjobsinusa.com/job-details-patent-attorney-job-san-diego-ca-organovo-holdings-inc
Lots of new job postings. https://organovo.jobs.net/search Interesting company Hampton. Somebody scooped up some Feb 17 $3 calls for $.70 today. Probably a good trade. hmph. We shall see. I like it. You might see more dilution though unless they get their revenues up. I don't see 400% anytime soon. I'm going to set up an rss feed on their patent applications though... in case they have something brewing we don't know about yet.